452 related articles for article (PubMed ID: 25110220)
1. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.
Ademi Z; Watts GF; Pang J; Sijbrands EJ; van Bockxmeer FM; O'Leary P; Geelhoed E; Liew D
J Clin Lipidol; 2014; 8(4):390-400. PubMed ID: 25110220
[TBL] [Abstract][Full Text] [Related]
2. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience.
Bell DA; Pang J; Burrows S; Bates TR; van Bockxmeer FM; Hooper AJ; O'Leary P; Burnett JR; Watts GF
Atherosclerosis; 2015 Mar; 239(1):93-100. PubMed ID: 25585028
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States.
Chen CX; Hay JW
Int J Cardiol; 2015 Feb; 181():417-24. PubMed ID: 25569270
[TBL] [Abstract][Full Text] [Related]
5. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
[TBL] [Abstract][Full Text] [Related]
6. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
[TBL] [Abstract][Full Text] [Related]
7. The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review.
Rosso A; Pitini E; D'Andrea E; Massimi A; De Vito C; Marzuillo C; Villari P
Ann Ig; 2017; 29(5):464-480. PubMed ID: 28715059
[TBL] [Abstract][Full Text] [Related]
8. Parent-child genetic testing for familial hypercholesterolaemia in an Australian context.
Pang J; Martin AC; Bates TR; Hooper AJ; Bell DA; Burnett JR; Norman R; Watts GF
J Paediatr Child Health; 2018 Jul; 54(7):741-747. PubMed ID: 29626384
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and Return on Investment of a Nationwide Case-Finding Program for Familial Hypercholesterolemia in Children in the Netherlands.
Ademi Z; Norman R; Pang J; Sijbrands E; Watts GF; Hutten BA; Wiegman A
JAMA Pediatr; 2023 Jun; 177(6):625-632. PubMed ID: 37126315
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.
Wonderling D; Umans-Eckenhausen MA; Marks D; Defesche JC; Kastelein JJ; Thorogood M
Semin Vasc Med; 2004 Feb; 4(1):97-104. PubMed ID: 15199439
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M
Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882
[TBL] [Abstract][Full Text] [Related]
12. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Marks D; Wonderling D; Thorogood M; Lambert H; Humphries SE; Neil HA
Health Technol Assess; 2000; 4(29):1-123. PubMed ID: 11109029
[TBL] [Abstract][Full Text] [Related]
13. Cascade genetic screening for familial hypercholesterolemia.
Leren TP
Clin Genet; 2004 Dec; 66(6):483-7. PubMed ID: 15521974
[TBL] [Abstract][Full Text] [Related]
14. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A
Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236
[TBL] [Abstract][Full Text] [Related]
15. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
Jensen HK
Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
[TBL] [Abstract][Full Text] [Related]
16. Screening for familial hypercholesterolaemia.
Bender R; Bell DA; Hooper AJ; Edwards G; van Bockxmeer FM; Watts GF; Burnett JR
Pathology; 2012 Feb; 44(2):122-8. PubMed ID: 22228254
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening.
Leren TP; Finborud TH; Manshaus TE; Ose L; Berge KE
Community Genet; 2008; 11(1):26-35. PubMed ID: 18196915
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia.
Lázaro P; Pérez de Isla L; Watts GF; Alonso R; Norman R; Muñiz O; Fuentes F; Mata N; López-Miranda J; González-Juanatey JR; Díaz-Díaz JL; Blasco AJ; Mata P
J Clin Lipidol; 2017; 11(1):260-271. PubMed ID: 28391894
[TBL] [Abstract][Full Text] [Related]
19. Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis.
Marquina C; Lacaze P; Tiller J; Riaz M; Sturm AC; Nelson MR; Ference BA; Pang J; Watts GF; Nicholls SJ; Zoungas S; Liew D; McNeil J; Ademi Z
Eur Heart J; 2022 Sep; 43(34):3243-3254. PubMed ID: 34788414
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
